000301475 001__ 301475
000301475 005__ 20250808115243.0
000301475 0247_ $$2doi$$a10.1038/s41375-025-02639-x
000301475 0247_ $$2pmid$$apmid:40374809
000301475 0247_ $$2ISSN$$a0887-6924
000301475 0247_ $$2ISSN$$a1476-5551
000301475 0247_ $$2altmetric$$aaltmetric:177148478
000301475 037__ $$aDKFZ-2025-01017
000301475 041__ $$aEnglish
000301475 082__ $$a610
000301475 1001_ $$0P:(DE-HGF)0$$aKühn, Michael W M$$b0
000301475 245__ $$aThe evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms.
000301475 260__ $$aLondon$$bSpringer Nature$$c2025
000301475 3367_ $$2DRIVER$$aarticle
000301475 3367_ $$2DataCite$$aOutput Types/Journal article
000301475 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1754646728_2116$$xReview Article
000301475 3367_ $$2BibTeX$$aARTICLE
000301475 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000301475 3367_ $$00$$2EndNote$$aJournal Article
000301475 500__ $$a39(8):1824-1837
000301475 520__ $$aResearch on myeloid neoplasms, a field that has been driving scientific advances in cancer for over 50 years, has yielded many discoveries that have fundamentally reshaped our understanding of cancer biology. These insights, often the product of leukemia research, have been instrumental in developing more mechanism-based treatments in the early 2000s [1]. Recognizing epigenetic dysregulation as a common disease mechanism in myeloid cancers has been groundbreaking regarding recent treatment developments that exploit chromatin-based oncogenic mechanisms. In the case of acute myeloid leukemia (AML), sequencing studies aimed at assessing the complement of genetic alterations demonstrated that more than 60% of AML cases harbored disease-driving mutations in epigenetic regulators. This high prevalence underscores the importance of epigenetic dysregulation in AML pathogenesis [2, 3]. Chromatin regulators commonly control disease-specific transcriptional programs, making them attractive therapeutic targets to manipulate neoplastic gene expression programs, particularly in myeloid neoplasms. Several drugs targeting epigenetic mechanisms and exploiting myeloid disease-specific dependencies have recently been approved for treating myeloid neoplasms. Many additional drugs are currently being investigated in clinical trials, and numerous new compound developments are being studied in preclinical studies. This manuscript will review (1) chromatin-based disease mechanisms, such as DNA methylation, chromatin regulatory complexes, and histone modifications, currently investigated for therapeutic exploitation in myeloid malignancies, and (2) therapeutic developments already approved or investigated for treating these diseases.
000301475 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000301475 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000301475 7001_ $$00000-0002-1670-6513$$aPemmaraju, Naveen$$b1
000301475 7001_ $$00000-0003-2438-1955$$aHeidel, Florian H$$b2
000301475 773__ $$0PERI:(DE-600)2008023-2$$a10.1038/s41375-025-02639-x$$n8$$p1824-1837$$tLeukemia$$v39$$x0887-6924$$y2025
000301475 909CO $$ooai:inrepo02.dkfz.de:301475$$pVDB
000301475 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000301475 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000301475 9141_ $$y2025
000301475 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-07$$wger
000301475 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000301475 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000301475 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000301475 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-07
000301475 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000301475 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-07
000301475 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-07
000301475 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000301475 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000301475 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLEUKEMIA : 2022$$d2025-01-07
000301475 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000301475 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000301475 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bLEUKEMIA : 2022$$d2025-01-07
000301475 9201_ $$0I:(DE-He78)FM01-20160331$$kFM01$$lDKTK Koordinierungsstelle Frankfurt$$x0
000301475 980__ $$ajournal
000301475 980__ $$aVDB
000301475 980__ $$aI:(DE-He78)FM01-20160331
000301475 980__ $$aUNRESTRICTED